Philadelphia Trust Co. Acquires 4,480 Shares of Illumina, Inc. $ILMN

Key Points

• Philadelphia Trust Co. increased its stake in Illumina, Inc. by 38.8% in the first quarter, owning 16,030 shares valued at approximately $1.27 million.
• Several institutional investors significantly boosted their holdings, with Capital World Investors increasing their stake by 408.6% to over 18 million shares.
• Illumina's stock has a current average rating of "Hold" with a consensus target price of $124.58 amid analyst revisions reflecting mixed sentiment.

Philadelphia Trust Co. lifted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 38.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,030 shares of the life sciences company's stock after buying an additional 4,480 shares during the quarter. Philadelphia Trust Co.'s holdings in Illumina were worth $1,272,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of ILMN. Capital World Investors lifted its stake in shares of Illumina by 408.6% during the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock valued at $2,408,721,000 after buying an additional 14,481,232 shares in the last quarter. Brown Advisory Inc. lifted its stake in shares of Illumina by 54,220.9% during the 4th quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company's stock valued at $255,586,000 after buying an additional 1,909,118 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Illumina by 2,057.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 922,281 shares of the life sciences company's stock valued at $73,174,000 after buying an additional 879,533 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Illumina by 3.5% during the 1st quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company's stock valued at $1,298,928,000 after buying an additional 558,243 shares in the last quarter. Finally, Pacer Advisors Inc. lifted its stake in shares of Illumina by 2,292.9% during the 1st quarter. Pacer Advisors Inc. now owns 565,680 shares of the life sciences company's stock valued at $44,881,000 after buying an additional 542,040 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Price Performance

Shares of NASDAQ:ILMN traded down $0.7420 during trading on Wednesday, reaching $100.8580. The company had a trading volume of 1,035,098 shares, compared to its average volume of 2,343,048. The company has a fifty day moving average of $97.39 and a two-hundred day moving average of $89.42. The stock has a market capitalization of $15.50 billion, a P/E ratio of 12.77, a price-to-earnings-growth ratio of 2.26 and a beta of 1.37. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. The firm had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business's revenue for the quarter was down 4.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Equities research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Robert W. Baird increased their target price on shares of Illumina from $84.00 to $105.00 and gave the stock a "neutral" rating in a research note on Monday, July 28th. Citigroup cut shares of Illumina from a "hold" rating to a "strong sell" rating and lowered their target price for the stock from $85.00 to $80.00 in a research note on Wednesday, July 9th. Wall Street Zen cut shares of Illumina from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Piper Sandler lowered their target price on shares of Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a research note on Thursday, May 15th. Finally, Daiwa America cut shares of Illumina from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 12th. Seven analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $124.58.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.